Module 3 Psychiatry notes Flashcards
First rank symptoms of Schizophrenia
3rd person auditory hallucinations Thought withdrawal, insertion and broadcast Delusional perceptions Delusions of control Somatic passivity
Schizophrenia positive symptoms
An excess or distortion of normal functioning Delusions, hallucinations and thought disorders Caused by overactivity of receptors in the mesolimbic pathway
Schizophrenia negative symptoms
Decrease or loss of functioning Blunting of affect, poverty of speech Caused by underactivity of receptors in the mesocortical pathway
Types of schizophrenia
Paranoid Catatonic Hebephrenic Residual Simple
Paranoid schizophrenia features
paranoid delusions, auditory hallucinations and perceptual disturbances
Catatonic schizophrenia features
hyperkinesis or negativism
Hebephrenic schizophrenia features
fluctuating affect
Residual schizophrenia features
long term negative symptoms
Simple schizophrenia features
negative symptoms without psychotic symptoms
First generation antipsychotics include/mechanism
Chlorpromazine, haloperidol, promazine, flupentixol and zuclopenthixol D2 antagonists, more potent than SGA due to increased occupancy of D2 receptors. Can worsen negative symptoms. Also block D2 receptors in nigrostriatal pathway causing extrapyramidal symptoms and in tuberoinfundibular pathway causing increased prolactin.
Second generation antipsychotics include/mechanism
ROCQAA- risperidone, olanzapine, clozapine, quetiapine, aripiprazole, amisulpride 5HT2A and D2 antagonists (dopamine, serotonin antagonists). High affinity for 5HT2A receptors than D2 receptors. Less extrapyramidal SE but more metabolic SE.
Third generation antipsychotics include/mechanism
Only licensed TGA is aripiprazole Dopamine partial agonists. Less SE but less efficacious.
Clozapine mechanism
SGA used in treatment resistant schizophrenia. Blocks D1 and D4 receptors, lower affinity for D2 receptors, also block 5HT2A receptors. Risk of agranulocytosis.
Significant Antipsychotic SEs
Pseudoparkinsonism Acute distonia Akathisia Tardive dyskinesia
Less significant antipsychotics SEs
Metabolic- weight gain, diabetes Anticholinergic- dry mouth, blurred vision, difficulty passing urine, urinary retention, constipation Anti-adrenergic- postural hypotension, tachycardia, sexual dysfunction Anti-histaminergic- sedation Cardiovascular (including prolonging the QT interval) Hormonal (including increasing plasma prolactin)
Acute dystonic reaction
Happens within a week or starting/increasing dose of antipsychotic Presentation: Mainly affects muscles of head and neck Torticollis, trismus, forceful protrusion of tongue, grimacing, oculogyric spasm, opisthotonos, blepharospasm Less commonly affects laryngeal/pharyngeal muscles- dyspshagia Management: Discontinue causative agent IM anticholinergic e.g. procyclidine
Neuroleptic Malignant Syndrome
Life threatening complication of antipsychotic medications. Presentation: hyperthermia (above 38°c), muscle rigidity, altered mental status, autonomic dysfunction (e.g. hypotension, incontinence) Elevated CK Management: ABCDE Stop causative agent IV benzos for agitation Cooling devices/antipyretics Treat rhabdomyolysis Sometimes bromocriptine and amantadine are used as muscle relaxants
ICD 10 classification of BPD
Two or more episodes in which the patient’s mood and activity levels are significantly disturbed At least one= hypomania (<4 days)/ mania (>7days)
DSM BPD types
Bipolar I- one or more manic episodes with or without a history of depressive episodes Bipolar II- one or more depressive episodes with at least one hypomanic episode
BPD mania symptoms
I DIG FAST Irritability/elevated mood Distractibility Inhibition loss Grandiosity Flight of ideas Activity increased Sleep not needed Talkative
Hypomania symptoms
Persistent mild elevation of mood Increased energy Marked feelings of well being Increased sociability Talkative Overfamiliar Increased sexual energy Hardly sleeping No impact on function
BPD treatments
Mood Stabilisers: Lithium Anticonvulsants: Valproate Lamotrigine +/- antipsychotics (haloperidol, olanzapine, quetiapine or risperidone) and antidepressants (fluoxetine) (Can try psychological treatment for depression)
Ebstein’s phenomenon
Ebstein’s anomaly is a congenital heart defect in which the septal and posterior leaflets of the tricuspid valve are displaced towards the apex of the right ventricle of the heart. In babies of mothers on lithium
Steven Johnson’s syndrome
Severe skin reaction to Lamotrigine
Valproate issue
Teratogenic
Lithium mechanism
Mechanism: inhibits cAMP production, cAMP inhibits monoamines so more monoamines available
Lithium safe level
Safe level: 0.6-1.0mmol/L
Lithium required monitoring
Li levels, U+E, TFTs, calcium
Lithium toxicity concentration
Toxicity: levels >1.5mmol/L
Lithium toxicity symptoms
Symptoms: tremor, anorexia, D+V, ataxia, dysarthria, delirium, fasciculations, hypotension, arrythmias, seizures, coma
Depression presentation
DEAD SWAMP Depressed mood Energy levels reduced Anhedonia Disturbed sleep Suicidal ideation Worthlessness Appetite reduced Mentation decreased (reduced concentration) Psychomotor retardation
Monoamine theory
Monoamine theory of depression where reduced monoamine function (5-HT, NA, DA) may cause depression. Precipitating factors: -Childhood trauma -Life events -Personality -Alcohol -Being female -Genetic -Illness